ReviewTrends in biotechnology2014
Chemically programmed antibodies.
Review in Trends in biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunoglobulins with Non-Canonical Functions in Inflammatory and Autoimmune Disease States.International journal of molecular sciences · 2020Pooled it
- DVD-IgG1 antibody-drug conjugates: Expanding the landscape of targeted cancer therapy.Current opinion in chemical biology · 2026Review
- G-Quadruplexes in the Regulation of Viral Gene Expressions and Their Impacts on Controlling Infection.Pathogens (Basel, Switzerland) · 2024Review
- A new immunochemical strategy for triple-negative breast cancer therapy.Scientific reports · 2021Article
- Phage engineering and the evolutionary arms race.Current opinion in biotechnology · 2021Review
- Chemically Programmable and Switchable CAR-T Therapy.Angewandte Chemie (International ed. in English) · 2020Article
- Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody-Drug Conjugates.Bioconjugate chemistry · 2019Article
- Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues.Cell chemical biology · 2019Article
- Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1.Frontiers in immunology · 2019Article
- Antibodies, synthetic peptides and related constructs for planetary health based on green chemistry in the Anthropocene.Future science OA · 2018Review
- Site-Specific Antibody Conjugation for ADC and Beyond.Biomedicines · 2017Review
- Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.Nature communications · 2017Article
- Site-specific chemical conjugation of human Fas ligand extracellular domain using trans-cyclooctene - methyltetrazine reactions.BMC biotechnology · 2017Article
- Stable and Potent Selenomab-Drug Conjugates.Cell chemical biology · 2017Article
- SMI-Ribosome inactivating protein conjugates selectively inhibit tumor cell growth.Chemical communications (Cambridge, England) · 2017Article
- Chemically Programmed Bispecific Antibodies in Diabody Format.The Journal of biological chemistry · 2016Article
- Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.Molecular pharmaceutics · 2015Article
- Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Journal of clinical pharmacology · 2015Review
- Chemical biology: How to minimalize antibodies.Nature · 2015Article
- Original insights on thrombospondin-1-related antireceptor strategies in cancer.Frontiers in pharmacology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Due to their unlimited chemical diversity, small molecules can rival monoclonal antibodies (mAbs) with respect to specificity and affinity for target molecules. However, key pharmacological properties of mAbs remain unmatched by small molecules. Chemical programming strategies have been developed for site-specific and covalent conjugation of small molecules to mAbs with unique reactivity centers. In addition to blending favorable features of small molecules and mAbs, chemically programmed antibodies (cpAbs) are economically attractive because they utilize the same mAb for an almost unlimited number of target molecule specificities, reducing manufacturing costs and shortening drug discovery and development time. Preclinical studies and clinical trials have begun to demonstrate the broad utility of cpAbs for the treatment and prevention of human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.